Legend Biotech (LEGN) Stock Price, News & Analysis

Company Overview

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

Key Stats

• Today's Range: $27.43 to $28.83
• 50-Day Range: $27.69 to $38.24
• 52-Week Range: $27.43 to $60.87
• Volume: 1.91 million shs
• Average Volume: 1.28 million shs
• Market Capitalization: $5.09 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $74.73
• Consensus Rating: Moderate Buy

Legend Biotech Stock Analysis - MarketRank™

Legend Biotech scored higher than 75% of companies evaluated by MarketBeat, and ranked 255th out of 927 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Legend Biotech has received a consensus rating of Moderate Buy. The company's average rating score is 2.92, and is based on 11 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Legend Biotech has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Legend Biotech are expected to grow in the coming year, from ($1.31) to ($0.53) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Legend Biotech is -29.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Legend Biotech is -29.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Legend Biotech has a P/B Ratio of 4.02. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.69% of the float of Legend Biotech has been sold short.

Short Interest Ratio / Days to Cover

Legend Biotech has a short interest ratio ("days to cover") of 5.1.

Change versus previous month

Short interest in Legend Biotech has recently decreased by 32.80%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Legend Biotech does not currently pay a dividend.

Dividend Growth

Legend Biotech does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.69% of the float of Legend Biotech has been sold short.

Short Interest Ratio / Days to Cover

Legend Biotech has a short interest ratio ("days to cover") of 5.1.

Change versus previous month

Short interest in Legend Biotech has recently decreased by 32.80%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 0.96

News Sentiment

Legend Biotech has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.79 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 16 news articles for Legend Biotech this week, compared to 6 articles on an average week.

Search Interest

3 people have searched for LEGN on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Legend Biotech to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Legend Biotech insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.02% of the stock of Legend Biotech is held by insiders.

Percentage Held by Institutions

70.89% of the stock of Legend Biotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

LEGN Stock Analysis - Frequently Asked Questions

How have LEGN shares performed this year?

Legend Biotech's stock was trading at $32.54 at the beginning of the year. Since then, LEGN shares have decreased by 14.9% and is now trading at $27.69.
View the best growth stocks for 2025 here.

How were Legend Biotech's earnings last quarter?

Legend Biotech Co. (NASDAQ:LEGN) posted its earnings results on Tuesday, May, 13th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.40) by $0.33. The company earned $195.05 million during the quarter, compared to analyst estimates of $190.83 million. Legend Biotech had a negative trailing twelve-month return on equity of 29.69% and a negative net margin of 66.92%.
Read the conference call transcript.

When did Legend Biotech IPO?

Legend Biotech (LEGN) raised $350 million in an initial public offering on Friday, June 5th 2020. The company issued 18,400,000 shares at a price of $18.00-$20.00 per share. Morgan Stanley, J.P. Morgan Securities and Jefferies served as the underwriters for the IPO.

Who are Legend Biotech's major shareholders?

Top institutional shareholders of Legend Biotech include Westfield Capital Management Co. LP (3.77%), Price T Rowe Associates Inc. MD (3.66%), Invesco Ltd. (1.60%) and Massachusetts Financial Services Co. MA (1.24%).

How do I buy shares of Legend Biotech?

Shares of LEGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Legend Biotech own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Legend Biotech investors own include NVIDIA (NVDA), Broadcom (AVGO), Adobe (ADBE), Meta Platforms (META), Arista Networks (ANET), Jabil (JBL) and e.l.f. Beauty (ELF).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 5/15/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:LEGN
• CIK: 1801198
• Web: www.legendbiotech.com
• Phone: 732-317-5050
• Fax: N/A
• Employees: 1,070
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $74.73
• High Stock Price Target: $90.00
• Low Stock Price Target: $55.00
• Potential Upside/Downside: +169.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.92
• Research Coverage: 12 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.59)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-518,250,000.00
• Net Margins: -66.92%
• Pretax Margin: N/A
• Return on Equity: -29.69%
• Return on Assets: -19.45%

Debt

• Debt-to-Equity Ratio: 0.27
• Current Ratio: 4.98
• Quick Ratio: 4.90

Sales & Book Value

• Annual Sales: $627.24 million
• Price / Sales: 8.11
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.88 per share
• Price / Book: 4.02

Miscellaneous

• Outstanding Shares: 183,649,000
• Free Float: 182,597,000
• Market Cap: $5.09 billion
• Optionable: Optionable
• Beta: 0.20